Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Tumor-Agnostic 2Other 2Head & Neck 2Genitourinary 2Endocrine 2NET 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 94Paclitaxel 85Gemcitabine 83Carboplatin 79Docetaxel 60Cisplatin 58Bevacizumab 58Nivolumab 56Fluorouracil 47Capecitabine 46Magnetic Resonance Spectroscopy 44Radiotherapy 41Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 37Pemetrexed 34Leucovorin 34Biopsy 34atezolizumab 33Cetuximab 32Standard of Care 31Trastuzumab 28Cyclophosphamide 28Radiosurgery 27Blood Specimen Collection 27Specimen Handling 26Sorafenib 26Ipilimumab 26Everolimus 26olaparib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Arginine × Tumor-Agnostic × Clear all
NCT03940053 2019-05-07

Prevention of Cancer Development and Progression

The First Affiliated Hospital of Zhengzhou University

Phase 3 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT02844387 2016-07-28

Supplementation of L-arginine in Patients With Non-resectable Brain Metastases

Instituto de Oncología Ángel H. Roffo

Phase 1/2 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡